Immune therapies for malignant mesothelioma.
Expert Rev Anticancer Ther
; 14(8): 965-73, 2014 Aug.
Article
en En
| MEDLINE
| ID: mdl-24833011
Malignant mesothelioma (MM) is a rare disease which can develop in pleura, pericardium or peritoneum and in which the therapies available have limited efficacy and are associated with various side effects. Therefore, there is a need for more targeted and more effective therapies which are able to halt the disease progression. Among them immune therapies actively or passively directed against various structures of the MM cells seem to be particularly promising given their inhibitory potential demonstrated in both experimental and early clinical studies. Mesothelin in particular seem to be not only a biomarker of disease activity but also a therapeutic target. This review discusses the immune therapies currently investigated for MM.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Terapia Molecular Dirigida
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Mesotelioma
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Rev Anticancer Ther
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Rumanía
Pais de publicación:
Reino Unido